An outbreak of holarctica-type tularemia in pediatric patients

Pediatric Infectious Disease Journal

Volumn 29, Issue 2, 2010, Pages 160-162

  Jounio, Ulla ^a   Renko, Marjo ^a   Uhari, Matti ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC ERROR; EPIDEMIC; FEMALE; FINLAND; FRANCISELLA TULARENSIS; HUMAN; INCIDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN MANIFESTATION; SUMMER; SYMPTOM; TULAREMIA;

EID: 75949123889     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b9a6b4     Document Type: Article

References (22)

1. Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann NY Acad Sci. 2007;1105:1-29.
2. Johansson A, Farlow J, Larsson P, et al. Worldwide genetic relationships among Francisella tularensis isolates determined by multiple-locus variable-number tandem repeat analysis. J Bacteriol. 2004;186:5808-5818.
3. Olsufjev NG, Meshcheryakova IS. Infraspecific taxonomy of tularemia agent Francisella tularensis McCoy et Chapin. J Hyg Epidemiol Microbiol Immunol. 1982;26:291-299.
4. Farlow JD, Wagner M, Dukerich M, et al. Francisella tularensis in the United States. Emerg Infect Dis. 2005;11:1835-1841.
5. Syrjälä H, Karvonen J, Salminen A. Skin manifestations of tularemia: a study of 88 cases in Northern Finland during 16 years (1967-1983). Acta Derm Venereol. 1984;64:513-516.
6. Eliasson H, Lindbäck J, Nuorti JP. The 2000 tularemia outbreak: a case-control study of risk factors in disease-endemic and emergent areas, Sweden. Emerg Infect Dis. 2002;8:956-960.
7. Tärnvik A, Berglund L. Tularemia. Eur Respir J. 2003;21:361-373.
8. Luotonen J, Syrjälä H, Jokinen K, et al. Tularemia in otolaryngologic practice. An analysis of 127 cases. Arch Otolaryngol Head Neck Surg. 1986;112:77-80.
9. Uhari M, Syrjälä H, Salminen A. Tularemia in children caused by Fran-cisella tularensis biovar palaearctica. Pediatr Infect Dis J. 1990;9:80-83.
10. Tärnvik A, Priebe HS, Grunow R. Tularemia in Europe: an epidemiological overview. Scand J Infect Dis. 2004;36:350-355.
11. Eliasson H, Bäck E. Tularemia in an emergent area in Sweden: an analysis of 234 cases in five years. Scand J Infect Dis. 2007;39:880-889.
12. Syrjälä H, Kujala P, Myllylä V, et al. Airborne transmission of tularemia in farmers. Scand J Infect Dis. 1985;17:371-375.
13. Meric M, Willke A, Finke EJ, et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS. 2008;116:66-73.
14. Luotonen J, Syrjälä H, Jokinen K, et al. Tularemia in otolaryngologic practice. An analysis of 127 cases. Arch Otolaryngol Head Neck Surg. 1986;112:77-80.
15. Jacobs RF, Narain JP. Tularemia in children. Pediatr Infect Dis. 1983;2: 487-491.
16. Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tulare-mia. Ann NY Acad Sci. 2007;1105:378-404
17. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics. 2006;118:1287-1292.
18. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196-1204.
19. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26:879-891.
20. Syrjälä H, Schildt R, Räisänen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991;10:68-70.
21. Ikäheimo I, Syrjälä H, Karhukorpi J, et al. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother. 2000;46:287-290.
22. Johansson A, Berglund L, Gothefors L, et al. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J. 2000;19:449-453.